6505--RFI - DRAFT SOW for PPV 2028 Amendment to Extend Response Date from July 2, 2026 to July 10, 2026 11:00AM CT.
Closed Pre-Solicitation Posted
- Solicitation number
- 36E79726Q0003
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs is conducting a Request for Industry Review and Comments on draft documentation for the Pharmaceutical Prime Vendor 2028 acquisition, with comments due by July 10, 2026 at 11:00 AM Central Time (deadline extended from July 2). This is a pre-solicitation RFI with no set-aside.
The PPV 2028 program will serve the VA, Federal Bureau of Prisons, Indian Health Service, and Immigration and Customs Enforcement Health Service Corps across approximately 800 participating accounts with potential monthly expansion. The contractor must maintain next-day delivery capability (or next scheduled delivery day for applicable facilities) with a minimum 98% daily fill rate and provide six complimentary emergency deliveries per facility monthly. Vendors must have minimum five years' experience as a pharmaceutical prime vendor and be Verified-Accredited Wholesale Distributors. Products include single and multiple source pharmaceuticals, generics, IV delivery systems, dietary supplements, blood-glucose monitoring units, and select medical/surgical items. Distribution fees are structured across six product categories: ultra-expensive medications (WAC ≥$30,000), GLP-1 injectables, specialty medications for chronic/complex/rare diseases, over-the-counter items, VA FSS and VA/DLA national contracts, and WBPG ANDA generics, with separate fee tiers for Fast Pay and NET 30 payment options.
The SOW requires electronic ordering systems with web-based and hand-held access, real-time pricing and inventory management, bar code scanning, Drug Supply Chain Security Act compliance including serialization, EDI transaction support, and comprehensive reporting. Training is provided at no cost. Expiration dating minimums vary by facility type (three to 20 months). Specialized requirements apply to Consolidated Mail Outpatient Pharmacies, IHS accounts, and facilities outside the continental United States.
Responses should include company name, point of contact, UEI and CAGE Code, and socioeconomic designations, sent to Karen.Ade@va.gov. Participation is voluntary and does not affect future solicitation eligibility. The formal solicitation number is 36W79726Q0001 (NAICS 325412).
Notice text
2 versions
Update #2 · Latest ·
Request for Industry Review and Comments on Draft Statement of Work (SOW) PPV 2028 Amendment to Extend Response Date from July 2 to July 10, 2026 11:00 AM CT.
Department of Veterans Affairs
Request for Industry Review and Comments on Draft Statement of Work (SOW)
Pharmaceutical Prime Vendor (PPV) 2028
The Department of Veterans Affairs (VA) is seeking industry review and feedback on the attached DRAFT Statement of Work (SOW), Definitions and Distribution Fee Categories for the Pharmaceutical Prime Vendor 2028 acquisition. This early engagement is intended to ensure the final SOW is clear, comprehensive and structured to support effective competition from qualified vendors.
Industry is invited to provide input including, but not limited to:
Identification of unclear, conflicting, or ambiguous requirements
Comments on technical or operational requirements that may affect performance
Suggestions related to distribution operations, inventory management, reporting, data exchange, or order fulfillment processes
Noted risks, barriers, or areas where additional definition would be beneficial
Suggestions to improve efficiency, or alignment with industry best practices
Industry feedback at this stage helps the VA refine requirements and improve acquisition outcomes. The VA may contact respondents for clarification of submitted comments. Feedback received may be considered in the development of subsequent SOW revisions and acquisition documentation. Participation in this review is voluntary and is not a prerequisite for participation in any future solicitation.
Submission Instructions:
Provide feedback no later than 11AM Central July 10, 2026
Send responses via email to Karen.Ade@va.gov
Include the following in your submission:
Company Name
Point of contact name, phone and email
UEI and CAGE Code
Socioeconomic designation(s), if applicable
Important Notes:
This announcement is not a solicitation and does not obligate the Government to issue a solicitation or award.
No contract will be awarded from this notice
Participation in this review (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation.
All feedback will be used for market research and SOW refinement purposes only.
The Government will not reimburse any costs associated with providing comments or participating in any related activities.
The VA appreciates industry s time and expertise in supporting the development of a strong, effective SOW for the PPV 2028 program.
The VA appreciates industry s participation in helping to shape a clear and effective SOW for the PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.
Update #1 ·
SUBJECT
Department of Veterans Affairs Pharmaceutical Prime Vendor 2028
GENERAL INFORMATION
CONTRACTING OFFICE S ZIP CODE
60141
SOLICITATION NUMBER
36W79726Q0001
RESPONSE DATE/TIME/ZONE
07-02-2026 11AM CENTRAL TIME, CHICAGO, USA
NAICS CODE
325412
CONTRACTING OFFICE ADDRESS
Department of Veterans Affairs
National Acquisition Center
National Contract Service
Bldg 37, PO Box 76
60141
POINT OF CONTACT
Karen Ade
Karen.Ade@va.gov
708-786-5231
DESCRIPTION
Department of Veterans Affairs
Request for Industry Review and Comments on Draft Statement of Work (SOW)
Pharmaceutical Prime Vendor (PPV) 2028
The Department of Veterans Affairs (VA) is seeking industry review and feedback on the attached DRAFT Statement of Work (SOW), Definitions and Distribution Fee Categories for the Pharmaceutical Prime Vendor 2028 acquisition. This early engagement is intended to ensure the final SOW is clear, comprehensive and structured to support effective competition from qualified vendors.
Industry is invited to provide input including, but not limited to:
Identification of unclear, conflicting, or ambiguous requirements
Comments on technical or operational requirements that may affect performance
Suggestions related to distribution operations, inventory management, reporting, data exchange, or order fulfillment processes
Noted risks, barriers, or areas where additional definition would be beneficial
Suggestions to improve efficiency, or alignment with industry best practices
Industry feedback at this stage helps the VA refine requirements and improve acquisition outcomes. The VA may contact respondents for clarification of submitted comments. Feedback received may be considered in the development of subsequent SOW revisions and acquisition documentation. Participation in this review is voluntary and is not a prerequisite for participation in any future solicitation.
Submission Instructions:
Provide feedback no later than 11AM Central July 2, 2026
Send responses via email to Karen.Ade@va.gov
Include the following in your submission:
Company Name
Point of contact name, phone and email
UEI and CAGE Code
Socioeconomic designation(s), if applicable
Important Notes:
This announcement is not a solicitation and does not obligate the Government to issue a solicitation or award.
No contract will be awarded from this notice
Participation in this review (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation.
All feedback will be used for market research and SOW refinement purposes only.
The Government will not reimburse any costs associated with providing comments or participating in any related activities.
The VA appreciates industry s time and expertise in supporting the development of a strong, effective SOW for the PPV 2028 program.
The VA appreciates industry s participation in helping to shape a clear and effective SOW for the PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.
Files
| File | Type | Posted |
|---|---|---|
| DRAFT PPV28 Definitions 06-11-2026.pdf | ||
| 36E79726Q0003 0001.docx | DOCX document | |
| DRAFT PPV28 Pricing Categories 06-11-2026.pdf | ||
| DRAFT PPV28 SOW 06-11-2026.pdf | ||
| DRAFT PPV28 Pricing Categories 6-11-2026.pdf | ||
| DRAFT PPV28 SOW 6-11-2026.pdf | ||
| 36E79726Q0003.docx | DOCX document | |
| DRAFT PPV28 Definitions 6-11-2026.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6505--Department of Veterans Affairs Pharmaceutical Industry Day | Veterans Integrated Service Network 12 | No set-aside | |
| Q517--36C25527Q0015 | Pharmacy Benefits Services | Wichita | | Veterans Integrated Service Network 15 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity